Claims for Patent: 5,985,322

Summary for Patent: 5,985,322

Title:	Method for the treatment of CNS disorders
Abstract:	An improved method for the treatment of central nervous system disorders comprises treating patients with an enteric fluoxetine formulation.
Inventor(s):	Anderson; Neil R. (West Lafayette, IN), Harrison; Roger F. (Zionsville, IN), Lynch; Daniel F. (Indianapolis, IN), Oren; Peter L. (Fishers, IN)
Assignee:	Eli Lilly and Company (Indianapolis, IN)
Application Number:	09/265,610
Patent Claims:	1. A method of treating people suffering from depression, obsessive-compulsive disorder, bulimia, pain, obsessive-compulsive personality disorder, post-traumatic stress disorder, hypertension, atherosclerosis, anxiety, anorexia nervosa, panic, social phobia, stuttering, sleep disorders, chronic fatigue, Alzheimer's disease, alcohol abuse, appetite disorders, weight loss, agoraphobia, amnesia, smoking cessation, nicotine withdrawal syndrome symptoms, disturbances of mood and/or appetite associated with pre-menstrual syndrome, depressed mood and/or carbohydrate craving associated with pre-menstrual syndrome, disturbances of mood, disturbances of appetite or disturbances which contribute to recidivism associated with nicotine withdrawal, circadian rhythm disorder, borderline personality disorder, hypochondriasis, pre-menstrual syndrome (PMS), late luteal phase dysphoric disorder, pre-menstrual dysphoric disorder, trichotillomania, symptoms following discontinuation of antidepressants, aggressive/intermittent explosive disorder, compulsive gambling, compulsive spending, compulsive sex, psychoactive substance use disorder, schizophrenia, premature ejaculation, or pyschiatric symptoms selected from the group consisting of stress, worry, anger, rejection sensitivity, and lack of mental or physical energy without an increase in nausea comprising administering an enteric fluoxetine pellet comprising a) a core consisting of fluoxetine and one or more pharmaceutically acceptable excipients; b) an optional seperating layer comprising a non-reducing sugar; c) an enteric layer comprising hydroypropylmethylcellulose acetate succinate (HPMCAS) and one or more pharmaceutically acceptable excipients; d) an optional finishing layer. 2. A method of claim 1, employing a formulation containing 20-100 mg base equivalent of fluoxetine. 3. A method of claim 1 employing a formulation containing about 90 mg base equivalent of fluoxetine. 4. A method of claim 1 wherein the fluoxetine is present as fluoxetine hydrochloride. 5. A method of claim 2 wherein the fluoxetine is present as fluoxetine hydrochloride. 6. A method of claim 3 wherein the fluoxetine is present as fluoxetine hydrochloride. 7. A method of claim 1 employing a formulation containing the following: 8. A method of claim 1 of treating people suffering from pain, further comprising the coadministration of morphine, codeine, or dextropropoxyphene. 9. A method of claim 8 employing a formulation containing 20-100 mg base equivalent of fluoxetine. 10. A method of claim 8 employing a formulation containing about 90 mg base equivalent of fluoxetine.